Osang Healthcare
오상헬스케어 · 036220
Health Care Medical Devices · KOSDAQ
Market cap US$71.4M (₩98.6B)
Overview
Osang Healthcare makes in-vitro diagnostic (IVD) products, devices and test kits that analyse blood, saliva, or other bodily fluids outside the body to detect disease, guide treatment, and inform prescriptions.
Its products span three diagnostic categories: biochemical tests (including portable blood-glucose and cholesterol monitors), immunoassay-based tests (such as quantitative analysers for cardiac, cancer, and hormonal conditions, and rapid antigen kits for respiratory infections), and molecular diagnostics that detect genetic material using PCR technology. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company distributes its products internationally, including through dedicated subsidiaries in the United States and Brazil.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$257.9M
- FY2024US$58.3M
- FY2025US$93.2M
Operating profit
- FY2023US$103.5M
- FY2024−US$18M
- FY2025US$1.8M
Net income
- FY2023US$84.5M
- FY2024−US$8.3M
- FY2025US$2.3M
Key ratios (FY2025)
Why it matters
Osang Healthcare operates dedicated distribution subsidiaries, OSANG LLC in the United States and OSANG DO BRASIL LIMITADA in Brazil, handling overseas sales directly rather than through third-party distributors.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?